AstraZeneca Annual Report and Operational Review 20 Form 20-F Information 2003 Sales growth is shown in both reported and underlying performance.
Reported performance takes into account all the factors including those which we cannot influence, principally currency exchange rates that have affected the results of our business.
Underlying performance shows sales growth at constant exchange rates CER to reflect the volume and price changes of the geographic and therapy areas and individual products by excluding the effects of exchange.
A description of the calculation of this measure is set out in the Financial Review on page 31, together with the reasons for its use.
Infection We aim to build a franchise in the treatment of infectious diseases by increasing sales of Merrem and by exploiting our traditional, structural and genomic-based technologies.
Key product performance 2003 2002 2001 2003 compared to 2002 2002 compared to 2001 Growth Growth due to due to Growth exchange Growth exchange Growth Growth Growth Growth Sales underlying effects Sales underlying effects Sales underlying reported underlying reported $m $m $m $m $m $m $m %% %% Merrem 346 46 15 285 59 1 227 16 21 26 26 Other 130 36 11155 17 1171 24 17 9 9 Total 476 10 26 440 42 398 28 11 11 Products Performance 2003 Therapy area overview Merrem Meronem meropenem is an Reported performance intravenous carbapenem antibiotic for the Sales grew by 8% on a reported basis, Infection world market value: treatment of serious hospital acquired rising by $36 million from $440 million $46 billion.
Clinical studies are in place to to $476 million.
support a supplementary new drug Infectious diseases cause more than application in the US in 2004 aimed at Underlying performance 11 million deaths each year.
securing an indication for skin and skin Sales of Merrem grew steadily by a further structure infections in 2005.
Growth World demand for antibiotics remains was largely attributable to sales outside high due to escalating resistance and Pipeline the US, which were up 19% to $283 million.
the increased risk of serious Our R&D facility in Boston, US is In the US sales grew by 7% to $63 million.
progressing a range of projects using traditional, structural and genomic based Performance 2002 technologies to deliver innovative antiReported performance 2003 in brief bacterial agents to the infection pipeline.
Infection sales rose from $398 million in 2001 to $440 million in 2002, a reported Steady underlying growth for Merrem In June 2003, our new R&D facility opened increase of 11%.
Work there is dedicated to finding a new treatment for tuberculosis, Underlying performance New laboratories opened in an infectious disease that is newly The underlying performance of 11% growth Bangalore, India, dedicated to finding diagnosed in approximately two million was driven by sales of Merrem which grew a new treatment for tuberculosis.
people every year in India and over eight by 26% for the full year to $285 million, million people worldwide.
chiefly on the 31% increase in sales outside the US.
In the US sales grew by 9% to $59 million.
Other infection products declined by 9%.
